CORE--CLINICAL

临床核心的主要目标将是在ADRC维持一个由375-400名志愿者患者和对照组组成的小组，以及100名志愿者患者和对照组，这是我们在Chula Vista的卫星诊所倡议的一部分，并招募有轻度认知障碍(定义为DRS&>109)的新D受试者，其中许多人将24/30离开MMSE&>以取代已变得更严重的受试者。在这一竞争性更新期间，我们将增加对特定患者群体和对照的招募，以满足研究需要。将特别强调招募80岁以上的对照人员，以满足对老年对照脑进行临床-病理对照的更多尸检的需要，满足对老年对照脑进行临床-病理对照的更多身体解剖的需要，以及满足那些研究遗传标记的人的需要(因为Apo-Eepsilon 4作为AD的主要易感因素在80岁后的作用减弱)。年度参与者评估将包括人口统计、历史、医学、神经学、精神病学和神经心理学检查，以帮助诊断并跟踪认知和神经进展的年度变化。这些评估提供了一个行为数据库，可供与ADRC相关的各种研究项目使用，此外，还提供了有关AD过程和进展的详细纵向数据。临床核心保存了成纤维细胞培养、DNA、血浆样本和脑脊液的库，供各种研究人员使用。临床核心中心提供了允许参与多中心试验和协作数据和基因分析的来源，并为圣地亚哥的其他D研究人员提供了一个具有良好特征的队列。最后，将开展开发工作，以提高我们早期诊断AD的能力，并改善对其他痴呆症的诊断，如与Lew小体相关的痴呆症和额颞痴呆。

The principle objective of the Clinical Core will be to maintain a panel of 375-400 volunteer patients and controls at the ADRC, and 100 volunteer patients & controls as part of our Hispanic initiative at our satellite clinic in Chula Vista, and to recruit new D subjects with a mild degree of cognitive impairment (defined as DRS>109, many of whom will leave MMSE >24/30 to replace subjects who have become more impaired. During the period of this competing renewal we will increase our recruitment of specific groups of patients and controls to meet research needs. Particular emphasis will be to recruit controls over the age of 80 in order to meet the need for a greater number of autopsies of elderly control brains for clinical-pathological correlations and to meet for a greater number of autopsies of elderly control brains for clinical-pathological correlations and to meet the needs of those studying genetic markers (since the effect of Apo-Eepsilon4 as the major susceptibility factor for AD diminishes after age 80). Annual participant evaluations will include demographic, historical, medical, neurological, psychiatric and neuropsychological examinations to aid in diagnosis and to track yearly changes in cognitive and neurological progression. The evaluations provide a behavioral data base that can be used by the various research projects associated with the ADRC and in addition, provide detailed longitudinal data on the course and progression of AD. The Clinical Core maintains banks of fibroblast cultures, DNA, plasma samples, and CSF that are used by a variety of investigators. The Clinical Core provides the sources that permits participation multicenter trials and collaboration data and genetic analysis, as well as supply a well characterized cohort to other D investigators in San Diego. Finally, developmental work will be undertaken to improve our ability to diagnose AD early and to improve the diagnosis of other dementias such as dementia associated with Lew bodies and fronto-temporal dementia.